RKIP does not contribute to MAP kinase pathway silencing in the Merkel Cell Carcinoma cell line UISO
2007

RKIP and MAP Kinase Pathway in Merkel Cell Carcinoma

Sample size: 1 publication Evidence: moderate

Author Information

Author(s): Roland Houben, Sonja Ortmann, Juergen C Becker

Primary Institution: Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Julius-Maximilians-Universität, Würzburg, Germany

Hypothesis

RKIP might be causative for MAP kinase pathway silencing in Merkel cell carcinoma.

Conclusion

RKIP expression is not critical for the inactivity of the MAP kinase pathway, proliferation properties, and sensitivity of MCC cells towards apoptosis-inducing agents.

Supporting Evidence

  • RKIP knock down did not induce any detectable phosphorylation of ERK.
  • Proliferation and chemosensitivity towards cisplatin were not altered upon knock down of RKIP.
  • The absence of phosphorylation of the MAP kinases ERK1 and ERK2 was not affected by RKIP knock down.

Takeaway

The study found that a protein called RKIP doesn't help turn on a pathway that helps cells grow in a type of skin cancer called Merkel cell carcinoma.

Methodology

RKIP expression was knocked down in UISO cells using siRNA, and the effects on MAP kinase pathway activity, proliferation, and chemosensitivity were assessed.

Participant Demographics

The MCC cell line UISO was established from a primary Merkel cell carcinoma of a 46-year-old woman.

Digital Object Identifier (DOI)

10.1186/1477-3163-6-16

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication